
Get in the KNOW
on LA Startups & Tech
XCanada-Based Field Trip Opens in Santa Monica, Joining a Growing Wave of Ketamine Clinics in LA
Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

By Tania Tbul's own admission, she's not "a drug person." But the memories of the sexual and physical abuse she endured starting at 12 stayed with her through a marriage, the birth of four children, a divorce and a handful of suicide attempts along the way.
And so, at the age of 45, she walked into Ketamine Clinics Los Angeles in Culver City.
"I was actually pulled out of my body and I was hugging my 12-year-old self and forgiving myself... I was actually out of my body," Tbul said about the first treatment. "After the first treatment, I felt like that gaping wound was starting to heal up. It was like closing up and it wasn't sore anymore."
The growing body of evidence that ketamine — once known as club drug "special k" — can be used to treat mental health disorders along with its increasing acceptance has caused a spring of clinics in Los Angeles ready to cash in on psychedelic mental health treatments. Ketamine Clinics Los Angeles was the first to open its doors to L.A. in 2014, and now Toronto-based psychedelic company Field Trip is establishing a presence in the city, utilizing ketamine as a vehicle for therapy.
"Cognitive behavioral therapy works, it just tends to take a long time to break down the defenses, get past the ego and get to really what's happening," said Field Trip co-founder Ronan Levy. "Psychedelic therapy just accelerates the process of breaking down those walls so you can start to do the work and the processing."
History of Ketamine
Developed in the wake of the Vietnam War, ketamine replaced phencyclidine (better known as PCP) as an anesthetic before its antidepressant properties were well-studied.
This allowed physicians like anesthesiologist Steven Mandel, who co-founded Ketamine Clinics Los Angeles in 2014, to use it for off-label purposes to treat depression and other mental health disorders.
At the same time, people were using it to get high. The Drug Enforcement Agency lists it as a Schedule 3 drug, along with low doses of codeine and testosterone.
In 2019, the FDA approved a version of ketamine called esketamine for mental health treatment. The drug is an antidepressant nasal spray. The move was a landmark for psychiatrists who were operating with an arsenal of oral drugs that stemmed from the 1950s.
"For the last 30 years, we've basically been using old old drugs," said David Olson, a professor at University of California, Davis. "And ketamine was really the first new exciting drug that worked differently than a lot of these previous drugs and that really opened up a whole bunch of new horizons."
Mandel has a brisk clientele. His Westchester clinic has administered more than 12,500 treatments, which consist of six ketamine intravenous treatments over a two- to three-week period. His patients run the gamut, from ages 18 and 80. Most come in for anxiety, post traumatic stress disorder and depression. But the treatments are also used to battle issues stemming from postpartum depression and suicidal ideation.
"Ketamine works for disorders, PTSD, and especially for suicidality — works in hours to a few days," he said. "This is the quickest, the safest and the most effective of all the agents that address major depression, bipolar depression and suicidality."
But the treatment has critics. Some argue the FDA was too eager to embrace the esketamine antidepressant, saying there wasn't enough evidence in the trials that the drug was better than a placebo. And, of course ketamine still has addictive properties.
Blue Cross Blue Shield Massachusetts is the only insurance company that covers intravenous ketamine injections. Treatments can cost thousands of dollars. Other insurance providers normally don't cover the procedure because it is not FDA approved, making it accessible only to those who can afford it.
Tbul came across ketamine while researching alternative treatments to the cocktail of medications she was put on as a child. She listened to a podcast interview in which Lamar Odom talked about using ketamine to cope with his struggles with mental health. Her daughter pointed out its reputation as a club drug, but after taking it, Tbul vehemently disagreed.
"It's completely wrong. Completely wrong," Tbul said. "It's somebody who's suffering from something they cannot erase from their mind."
Tbul's first treatment at Ketamine Clinics Los Angeles, in which she said she was able to console her teenage self, allowed her to forgive herself for the emotions that had weighed her down for years.
"After the treatment, it's like an acceptance. I'm very at peace with my own body," Tbul said.
The experience is common. Often patients say the drug allows them to confront traumatic situations from a distance, and look at situations with more objectivity and empathy.
New Drug Horizons
There are more than two hundred ketamine clinics scattered across the U.S., but Santa Monica caught the eye of Field Trip, which opened a clinic in September with the goal of collecting data from ketamine-based therapy sessions and studying the effects of psychedelic drugs, while also developing and testing its own psilocybin-based treatments.
"Because we're going to have access to so much data about what makes a difference in these therapies, we can actually take that data and make sure that when we pair the therapy with our own products, we're going to get to the best outcomes," co-founder Levy said.
The Canadian company — created in 2019 by former cannabis startup founders — is best known for its research and development into psychedelic drugs. The company rolled out an app to enhance the psychedelic experience and went public in October on Canada's stock exchange.
The clinic is outfitted with mid-century furniture, fluffed-up cushions and shaggy rugs, almost like an Architectural Digest spread came to life. In-person ketamine injections and subsequent therapy sessions at its Santa Monica center offer depression, anxiety and PTSD-related treatments for upwards of $5,000.
Ketamine Administration Room
It's a hefty price for depression treatment (insurance doesn't cover it — the ketamine injection at Field Trip is administered through the muscle, not the vein). The price covers six sessions, each involving a ketamine shot that lasts 45 minutes to an hour followed by traditional psychotherapy administered by trained therapists. The process, Levy said, is meant to make therapy sessions more productive and allow patients to get more out of each session.
"The psychiatrist's arsenal — what they use to treat these illnesses — a lot of these drugs were identified kind of by accident many, many years ago and haven't really identified anything new," Olson said.
The world looks much different now.
Alternative treatments to health problems are becoming increasingly popular, and legal bodies are working to invest in their research. Oregon became the first state to legalize psychedelic mushrooms to treat depression — though the rules and restrictions around it are still being hammered out — and the FDA is conducting clinical trials on the efficacy of psilocybin as a mental health treatment. Field Trip itself is researching and developing psilocybin-based treatments.
Meanwhile, innovation around ketamine has fallen by the wayside, in part due to the fact the patent expired in 2002. Any new drugs that could emerge from it, through financially-intensive research and development and clinical trials, would not be as profitable as new patented compounds.
"They're super, super expensive," Olson said. "Companies want to ensure they can recoup those costs associated with the development."
Even as ketamine clinics continue to pop up their development, experts said, is likely to be limited. But, the use of these once recreational drugs isn't likely to die down for people like Tbul who are willing to shell thousands of dollars every year for treatment.
"I wish it was more accessible to people who are really suffering," she said. "Because not everybody can afford how much it costs per treatment."
Lead art by Carolyn Figel.
- Psilocybin Mushroom Treatment for Mental Health Is Coming - dot.LA ›
- Tripp Raises $11 Million to Simulate Psychedelic Euphoria - dot.LA ›
- Ketamines for Depression Now Come as an Injection - dot.LA ›
- VR Therapy App Tripp Acquires Meditation Startup EvolVR - dot.LA ›
- Los Angeles Ketamine Clinic — California Center for Psychedelic ... ›
- Los Angeles Psychedelic Therapy Clinic | Field Trip Health ›
- Ketamine Healing Clinic of Los Angeles ›
- Ketamine Clinics Los Angeles ›
- Ketamine clinics promise depression treatment, but some stray from ... ›
- The Ketamine Clinic Craze: Legalities and Possibilities - Canna Law ... ›
Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.
Subscribe to our newsletter to catch every headline.
Plus Capital Partner Amanda Groves on Celebrity Equity Investments
On this episode of the L.A. Venture podcast, Amanda Groves talks about how PLUS Capital advises celebrity investors and why more high-profile individuals are choosing to invest instead of endorse.
As a partner at PLUS, Groves works with over 70 artists and athletes, helping to guide their investment strategies. PLUS advises their talent roster to combine their financial capital with their social capital and focus on five investment areas: the future of work, future of education, health and wellness, the conscious consumer and sustainability.
“The idea is if we can leverage these people who have incredible audiences—and influence over that audience—in the world of venture capital, you'd be able to help make those businesses move forward faster,” Groves said.
PLUS works to create celebrity partnerships by identifying each client’s passions and finding companies that align with them, Groves said. From there, the venture firm can reach out to prospective partners from its many contacts and can help evaluate businesses that approach its clients. Recently, PLUS paired actress Nina Dobrev with the candy company SmartSweets after she had told them about her love for its snacks.
Celebrity entrepreneurship has shifted quite a bit in recent years, Groves said. While celebrities are paid for endorsements, Groves said investing allows them to gain equity from the growth of companies that benefit from their work.
“Like in movies, for example, where they're earning a residual along the way, they thought, ‘You know, if we're going to partner with these brands and create a tremendous amount of enterprise value, we should be able to capture some of the upside that we're generating, too’,” she said.
Partnering in this way also allows her clients to work with a wider range of brands, including small brands that often can’t afford to spend millions on endorsements. Investing allows high-profile individuals to represent brands they care about, Groves said.
“The last piece of the puzzle was a drive towards authenticity,” Groves said. “A lot of these high-profile artists and athletes are not interested, once they've achieved some sort of level of success, in partnering with brands that they don't personally align with.”
Hear the full episode by clicking on the playhead above, and listen to LA Venture on Apple Podcasts, Stitcher, Spotify or wherever you get your podcasts.
dot.LA Editorial Intern Kristin Snyder contributed to this post.
Rivian Stock Roller Coaster Continues as Amazon Van Delivery Faces Delays
David Shultz is a freelance writer who lives in Santa Barbara, California. His writing has appeared in The Atlantic, Outside and Nautilus, among other publications.
Rivian’s stock lost 7% yesterday on the back of news that the company could face delays in fulfilling Amazon’s order for a fleet of electric delivery vans due to legal issues with a supplier. The electric vehicle maker is suing Commercial Vehicle Group (CVG) over a pricing dispute related to the seats that the supplier promised, according to the Wall Street Journal.
The legal issue could mean that Amazon may not receive their electric vans on time. The dispute hinges on whether or not Commercial Vehicle Group is allowed to raise the prices of its seats after Rivian made engineering and design changes to the original version. Rivian says the price hike from CVG violates the supply contract. CVG denies the claim.
Regardless, the dispute could hamper Rivian’s ability to deliver electric vans to Amazon on time. The ecommerce/streaming/cloud computing/AI megacorporation controls an 18% stake in Rivian as one of the company’s largest early investors. Amazon has previously said it hopes to buy 100,000 delivery vehicles from Rivian by 2030.
The stock plunge marked another wild turn for the EV manufacturer. Last week, Rivian shares dropped 21% on Monday after Ford, another early investor, announced its intent to sell 8 million shares. The next few days saw even further declines as virtually the entire market saw massive losses, but then Rivian rallied partially on the back of their earnings report on Wednesday, gaining 28% back by Friday. Then came yesterday’s 7% slide. Today the stock is up another 10%.
Hold on tight, who knows where we’re going next.
David Shultz is a freelance writer who lives in Santa Barbara, California. His writing has appeared in The Atlantic, Outside and Nautilus, among other publications.
Snapchat’s Attempt to Protect Young Users From Third-Party Apps Falls Short
Kristin Snyder is an editorial intern for dot.la. She previously interned with Tiger Oak Media and led the arts section for UCLA's Daily Bruin.
Some Snap Kit platform developers have skirted guidelines meant to make the app safer for children.
A new report from TechCrunch released Tuesday found that some third-party apps that connect to users’ Snap accounts have not been updated according to new guidelines announced in March. The restrictions, which target anonymous messaging and friend-finding apps, are meant to increase child safety. However, the investigation found a number of apps either ignore the new regulations or falsely claim to be integrated with Snapchat.
The Santa Monica-based social media company announced the changes after facing two separate lawsuits related to teen suicide allegedly caused by the app. Over 1,500 developers integrate Snap features like the camera and Bitmojis. Snap originally claimed the update would not affect many apps.
Developers had 30 days to revise their software, but the investigation found that some apps, such as the anonymous Q&A app Sendit, were granted an extension. Others blatantly avoided the changes—the anonymous messaging app HMU, which is now meant for adult users, is still available to users "9+" in the App Store. Certain apps that have been banned from Snap, like Intext, still advertise Snapchat integration.
“First and foremost, we put the privacy and safety of our community first and expect the products built by our developer community to adhere to that standard in addition to bringing fun and positive experiences to people,” Director of Platform Partnerships Alston Cheek told TechCrunch.
The news is a blow to Snap’s recent efforts to cast itself as a responsible social media platform The company recently announced Colleen DeCourcy would take over as the company’s new chief creative officer and CEO Evan Spiegel to recently made a a generous personal donation to graduates of Otis College of Art and Design. The social media company currently faces a lawsuit from a teenager who claims it has not done enough to protect minors from sexual exploitation. In April, 44 attorney generals sent a letter to Snap and TikTok urging the companies to strengthen parental controls.
Lawmakers are considering new policies that would hold social media companies accountable for the content on their platforms. One such bill would require social media companies to share data with independent researchers.
Snapchat recently rolled out augmented reality shopping features and influencer-led original content to grow its younger base of users.
Snap Inc., Snapchat's parent company, is an investor in dot.LA.
Kristin Snyder is an editorial intern for dot.la. She previously interned with Tiger Oak Media and led the arts section for UCLA's Daily Bruin.